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Abstract 
This report describes the production and certification of ERM-DA483/IFCC, a serum protein reference material intended for the standardisation of 
measurements of immunoglobulin G proteinase 3 anti-neutrophil cytoplasmic autoantibodies (IgG PR3 ANCA). The material was produced according to ISO 
Guide 34:2009 [ ] and is certified in accordance with ISO Guide 35:2006. 
The raw material used to prepare ERM-DA483/IFCC was a plasmapheresis material containing a high concentration of IgG PR3 ANCA. After a prior 
commutability study lyophilised serum was selected as the best format for the reference material. The processing of the serum was based on the 
procedure used for the reference material ERM-DA470k/IFCC [3]. The plasma was converted into serum which was then delipidated. After the addition of 
preservatives the processed serum was diluted with plasmapheresis buffer containing albumin, prior to the transfer of 1 mL aliquots to glass vials. The 
serum was then lyophilised and the vials were closed with rubber stoppers and screw caps under argon atmosphere prior to storage at -70 °C.  
The between unit-homogeneity was quantified and stability during dispatch and storage was assessed in accordance with ISO Guide 35:2006.  
The material was characterised by an inter-laboratory comparison exercise performed by laboratories of demonstrated competence, using a purified IgG 
PR3 ANCA preparation as calibrant. This was achieved by applying a value transfer protocol previously used in the characterisation of ERM-DA470k/IFCC. 
Technically invalid results were removed, but no outliers were eliminated on statistical grounds alone.  
The uncertainty of the certified value was estimated in accordance to the Guide to the Expression of Uncertainty in Measurement (GUM) and included 
components relating to possible lack of homogeneity, stability and the property value measured during characterisation. 
The main purpose of this material is to be used for the calibration of immunoassay-based in vitro diagnostic devices or control products for IgG PR3 ANCA 
measurements. As any reference material, it can also be used for control charts or validation studies. The CRM is available in glass vials containing 
approximately 0.1 g of dried powder. The minimum sample intake to be used after reconstitution of the material is 5 µL. 
The CRM was accepted as European Reference Material (ERM®) after peer evaluation by the partners of the European Reference Materials consortium.
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Summary 
This report describes the production and certification of ERM-DA483/IFCC, a serum protein 
reference material intended for the standardisation of measurements of immunoglobulin G 
proteinase 3 anti-neutrophil cytoplasmic autoantibodies (IgG PR3 ANCA). The material was 
produced according to ISO Guide 34:2009 [1] and is certified in accordance with ISO Guide 
35:2006 [2]. 
The raw material used to prepare ERM-DA483/IFCC was a plasmapheresis material 
containing a high concentration of IgG PR3 ANCA. After a prior commutability study 
lyophilised serum was selected as the best format for the reference material. The processing 
of the serum was based on the procedure used for the reference material ERM-
DA470k/IFCC [3]. The plasma was converted into serum which was then delipidated. After 
the addition of preservatives the processed serum was diluted with plasmapheresis buffer 
containing albumin, prior to the transfer of 1 mL aliquots to glass vials. The serum was then 
lyophilised and the vials were closed with rubber stoppers and screw caps under argon 
atmosphere prior to storage at -70 °C.  
The between unit-homogeneity was quantified and stability during dispatch and storage was 
assessed in accordance with ISO Guide 35:2006 [2].  
The material was characterised by an inter-laboratory comparison exercise performed by 
laboratories of demonstrated competence, using a purified IgG PR3 ANCA preparation as 
calibrant. This was achieved by applying a value transfer protocol previously used in the 
characterisation of ERM-DA470k/IFCC [3]. Technically invalid results were removed, but no 
outliers were eliminated on statistical grounds alone.  
The uncertainty of the certified value was estimated in accordance to the Guide to the 
Expression of Uncertainty in Measurement (GUM) [4] and included components relating to 
possible lack of homogeneity, stability and the property value measured during 
characterisation. 
The main purpose of this material is to be used for the calibration of immunoassay-based in 
vitro diagnostic devices or control products for IgG PR3 ANCA measurements. As any 
reference material, it can also be used for control charts or validation studies. The CRM is 
available in glass vials containing approximately 0.1 g of dried powder. The minimum sample 
intake to be used after reconstitution of the material is 5 µL. 
The CRM was accepted as European Reference Material (ERM®) after peer evaluation by 
the partners of the European Reference Materials consortium. 
The following value was assigned: 
 
Mass Concentration  
Certified value 2) 
[mg/L] 
Uncertainty 3) 
[mg/L] 
IgG PR3 ANCA 1) 270 29 
1) Proteinase 3 anti-neutrophil cytoplasmic antibodies as measured by immunoassays 
2) Unweighted mean value of the means of 10 accepted data sets each set obtained in a different laboratory and/or 
with a different method of determination. The certified mass concentration and its uncertainty are traceable to the 
stated value of the mass concentration in United States National Reference Preparation (USNRP) 12-0575C (Reimer 
et al., Am J Clin Pathol 77 (1982) 12-19) 
3) The uncertainty is the expanded uncertainty of the certified value with a coverage factor k = 2 corresponding to a 
level of confidence of about 95 % estimated in accordance with ISO/IEC Guide 98-3, Guide to the Expression of 
Uncertainty in Measurement (GUM:1995), ISO, 2008 
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Glossary 
ANCA 
ANOVA  
Anti-neutrophil cytoplasmic antibodies 
Analysis of variance 
b Slope in the equation of linear regression y = a + bx 
cIgG PR3 ANCA 
cERM-DA483/IFCC 
Concentration of the purified IgG PR3 ANCA 
Concentration of IgG PR3 ANCA in ERM-DA483/IFCC 
CLSI Clinical and Laboratory Standards Institute 
CRM 
df 
Certified Reference Material 
Degrees of freedom 
EC European Commission 
ELISA 
EQAS 
Enzyme-linked immunosorbent assay 
External quality assurance scheme 
ERM® Trademark of European reference materials 
EU European Union 
GUM Guide to the expression of uncertainty in measurements  
IFCC International Federation of Clinical Chemistry and Laboratory Medicine 
IgG Immunoglobulin G 
ISO International Organization for Standardization  
IU International units 
IVD-MD In Vitro Diagnostic - Medical Devices 
JRC Joint Research Centre  
k Coverage factor 
MS
 
Mean of squares 
MSbetween Mean of squares between-unit from an ANOVA 
MSwithin  Mean of squares within-unit from an ANOVA 
n
 
Number of replicates per unit 
PES 
PR3 ANCA 
QC 
Polyethersulfone  
Proteinase 3 anti-neutrophil cytoplasmic antibodies 
Quality control 
rel 
RLU 
RM 
Index denoting relative figures (uncertainties etc.) 
Relative Light Units  
Reference material 
RSD Relative standard deviation 
RT Room temperature 
R2 Coefficient of determination of the linear regression 
s Standard deviation 
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sbb Between-unit standard deviation; an additional index "rel" is added when 
appropriate 
sbetween
 Standard deviation between groups as obtained from ANOVA; an 
additional index "rel" is added as appropriate 
SEC 
sijk 
Size exclusion chromatography 
Signal of the kth measurement of material i within dilution j 
SS Sum of squares 
swithin Standard deviation within groups as obtained from ANOVA; an additional 
index "rel" is added as appropriate 
swb Within-unit standard deviation 
T Temperature 
t 
ti 
t  
Time 
Time elapsed at time point i 
Mean of all ti 
tα, df Critical t-value for a t-test, with a level of confidence of 1-α and df 
degrees of freedom 
tsl 
ttt 
TIU
 
Chosen shelf life 
Chosen transport time 
Trypsin inhibitor unit 
TM Target material 
TF Transfer factor 
TRIS Tris(hydroxymethyl)aminomethane 
u Standard uncertainty  
U 
ub 
ubal 
Expanded uncertainty 
Standard uncertainty of the slope 
Standard uncertainty relating to the balance; an additional index "rel" is 
added as appropriate 
u*bb  Standard uncertainty relating to a maximum between-unit inhomogeneity 
that could be hidden by method repeatability; an additional index "rel" is 
added as appropriate 
ubb Standard uncertainty relating to a possible between-unit inhomogeneity;  
an additional index "rel" is added as appropriate 
uc Combined standard uncertainty; an additional index "rel" is added as 
appropriate 
uchar,cal Standard uncertainty of the calibrant characterisation; an additional index 
"rel" is added as appropriate 
uchar  Standard uncertainty of the material characterisation; an additional index 
"rel" is added as appropriate 
uCRM Combined standard uncertainty of the certified value; an additional index 
"rel" is added as appropriate 
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UCRM  
 
Expanded uncertainty of the certified value; an additional index "rel" is 
added as appropriate 
uERM-DA470k/IFCC Standard uncertainty of the certified value for ERM-DA470k/IFCC 
u∆ Combined standard uncertainty of measurement result and certified 
value 
ults Standard uncertainty of the long-term stability; an additional index "rel" is 
added as appropriate 
upur Standard uncertainty for the purity of the calibrant; an additional index 
"rel" is added as appropriate 
usts 
 
Standard uncertainty of the short-term stability; an additional index "rel" 
is added as appropriate 
USNRP United States National Reference Preparation 
UV Ultraviolet 
y  Mean of all results of the homogeneity study 
α Significance level 
∆meas Absolute difference between mean measured value and the certified 
value 
νMSwithin 
WG-HAT 
Degrees of freedom of MSwithin 
Working Group – Harmonisation of Autoantibody Tests 
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1. Introduction  
1.1. Background 
 
Autoimmune antibodies are important analytes in laboratory medicine. The measurement of 
their concentrations is used in routine medical evaluations and in a large number of specific 
indications, and can be performed repeatedly.  
In 2009 the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) 
formed a new working group with a mandate for the Harmonisation of Autoantibody Tests 
(WG-HAT). The detection and quantification of IgG antibodies to autoantigens are important 
for the diagnosis and monitoring of a number of autoimmune diseases. For every 
autoantibody in routine use, there is currently marked diversity in the response of analysis 
methods and the materials used for assay calibration. There are materials designated as 
standards for some of these methods, however they are not fully characterised and are often 
used inconsistently. This generates large variability in the analyses results (as shown in the 
external quality assurance scheme (EQAS) results), possible misdiagnosis and a potential 
delay in the diagnosis or in the follow-up of the disease.  
The immunoassays used for the measurement of autoimmune antibodies are convenient in a 
clinical setting because they give fast results. They can be sensitive and specific, if designed 
properly. The signal is dependent on a large number of factors including the antibody 
specificity, reaction kinetics and equilibria, multimeric state of the proteins, complex matrix 
effects, etc. Therefore quantification with immunoassays requires the use of a proper 
calibrant.  
One type of antibodies selected by IFCC for quantification and standardisation are the 
antibodies associated with an autoimmune condition known as small vessel vasculitis. This 
condition is mediated by antibodies against the neutrophil enzyme proteinase 3 (PR3) and 
myeloperoxidase (MPO). IgG PR3 ANCA are found in about 80 % of patients with Wegener's 
granulomatosis, and in about 35 % of patients with microscopic polyangiitis, Churg-Strauss 
syndrome, and renal-limited rapidly progressive glomerulonephritis [5, 6].  
These antibodies are detected as anti-neutrophil cytoplasmic antibodies (C-ANCA) and 
represent the cornerstones of the diagnosis of small vessel-associated vasculitis together 
with MPO ANCA [7]. JRC has already developed and produced a certified reference material 
(CRM), against IgG MPO ANCA [8]. This new material, presented in the current report, 
against IgG PR3 ANCA, aims to fill the gap in the standardisation of measurements of IgG 
ANCA for small vessel-associated vasculitis. 
The EU Directive on In Vitro Diagnostic Medical Devices (IVD-MD) (Directive 98/79/EC) 
requires traceability of calibrants and control materials to reference measurement procedures 
and/or reference materials of higher order. 
A calibrant must have an assigned value that is metrologically traceable, and accompanied 
by an uncertainty statement. The stability and homogeneity of the material with respect to the 
certified property must be verified, and the calibrant must be commutable, i.e. resemble the 
patient samples [9]. These attributes are particularly challenging for serum protein calibrants, 
as they form a mixture of interacting proteins with different isoforms and complexes.  
8 
1.2. Choice of the material 
 
The requirements for a material to be used as a reference material for the calibration of 
immunoassay-based in vitro diagnostic devices or for analysis products for IgG PR3 ANCA 
are, in addition to requirements for homogeneity, stability, value traceability and 
commutability: 
 The concentration of the target protein in the final material should be high enough so 
that dilutions of the material can cover the relevant part of the measurement interval 
of the methods.  
 For the successful reproduction of the material, materials produced consecutively 
must be consistent. This is an important issue in clinical chemistry, as the use of 
reference ranges and decision limits requires that measurement results are 
comparable over long periods of time. 
According to a prior commutability study performed (Section 8) the raw material selected for 
IgG PR3 ANCA was sufficiently commutable to lead to a considerable reduction of inter-
assay variability. Therefore it was decided to produce the new material according to the 
procedure described below.  
 
1.3. Work-flow 
 
After a thorough commutability study a plasmapheresis material with a high concentration of 
IgG PR3 ANCA was selected as the starting material. It was converted into serum and 
processed according to the procedure used for the reference material ERM-DA470k/IFCC. 
The procedure consists of delipidation followed by the addition of preservatives (Section 3.2). 
The processed serum was then transferred to vials (1 mL serum per vial) and lyophilised. 
The vials were closed under argon with rubber stoppers and screw caps and were then 
stored at -70 °C.  
The homogeneity, short term and long term stability of the material were assessed for the 
mass concentration of IgG PR3 ANCA.  
A calibration solution was prepared and characterised so as to allow the characterisation of 
ERM-DA483/IFCC. IgG PR3 ANCA was purified from plasmapheresis material, the same 
material used for preparing the certified reference material (CRM), by a combination of 
affinity chromatography and size exclusion chromatography (Section 6.3). A value for the IgG 
mass concentration in the calibrant was assigned using three routine methods selective for 
total IgG (based on either turbidimetry or nephelometry) repeated in two separate days. The 
value assignment of the calibration solution was performed using ERM-DA470k/IFCC as a 
calibrant.  
A property value was assigned to ERM-DA483/IFCC by using this purified IgG PR3 ANCA 
calibration solution and routine IgG PR3 ANCA procedures (ELISA, chemiluminescent and 
fluorescence immunoassays). This was achieved by using a value transfer protocol that can 
be considered as reference procedure [10]. Therein eight dilutions of the target material were 
measured in parallel with eight dilutions of the calibrant. The concentration of the target 
material was determined against the calibrant solution (Figure 1). The procedure is described 
in detail in Section 6.2. The traceability chain is described in Section 8. 
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Figure 1: Scheme for the production and characterisation of the calibrant (purified IgG PR3 
ANCA) and of the CRM (ERM-DA483/IFCC). 
 
2. Participants 
2.1. Provision of raw materials  
• Statens Serum Institute, Amager, DK  
 
2.2. Project management, evaluation and processing 
• European Commission, Joint Research Centre, Directorate for Health, Consumers & 
Reference Materials, Reference Materials Unit (F.6), Geel, BE (accredited according 
to ISO Guide 34 BELAC 268-RM) 
 
2.3. Homogeneity and stability studies 
• European Commission, Joint Research Centre, Directorate for Health, Consumers & 
Reference Materials, Reference Materials Unit (F.6), Geel, BE (accredited according 
to ISO/IEC 17025 BELAC 268-RM) 
• INOVA Diagnostics, INC., San Diego, US  
• ORGENTEC Diagnostika GmbH, Mainz, DE  
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2.4. Characterisation 
• AESKU Diagnostics GmbH & Co., Wendelsheim, DE  
• Bio-Rad Laboratories INC., California, US  
• CERBA specimen services, Saint-Ouen l'Aumône, FR (accredited to ISO 
15189:2012, COFRAC, N 8-0945 rev. 6) 
• EUROIMMUN Medizinische Labordiagnostika AG, Dassow, DE  
• EuroDiagnostica AB, Malmö, SE  
• IMMCO Diagnostics, Buffalo, US  
• INOVA Diagnostics INC., San Diego, US  
• Lund University, Lund, SE  
• ORGENTEC Diagnostika GmbH, Mainz, DE  
• Protein Reference Unit, St. Georges Hospital, London, UK (accredited to ISO 
15189:2012, UKAS CPA 1929) 
• Phadia / Thermo Fisher Scientific, Freiburg, DE  
• Roche Diagnostics GmbH, Penzberg, DE  
• Siemens Healthcare Diagnostics Products GmbH, Marburg, DE  
 
3. Material processing and process control 
3.1. Origin of the starting material 
 
The raw material used to produce ERM-DA483/IFCC was a plasmapheresis material 
collected from patients diagnosed with an autoimmune, non-infectious disease, provided by 
Statens Serum Institute (DK). It was tested and found to be negative for Hepatitis B surface 
antigen, HIV 1&2 antibodies, HIV antigen and Hepatitis C antibodies. 
 
3.2. Processing and processing control 
3.2.1. Plasma conversion into serum 
An aliquot (1 L) of the plasmapheresis material was thawed and warmed to 37 °C.  
A volume of 10 mL (5 mg/mL) protamine sulfate solution (Sigma-Aldrich, DE) was then 
added and the material stirred for ten min at 37 °C. Following an incubation of one hour at 
room temperature (RT) the material was further incubated at 4 °C for 40 h to allow the 
formation of fibrin. Fibrin was then removed by centrifugation at 16880 g for ten min 
whereupon the supernatant was filter-sterilized through a 0.22 µm PES filter (Corning Inc., 
US). 
11 
3.2.2. Serum processing 
 
The procedure for the processing of serum was based on that used for ERM-DA470k/IFCC 
[11]. Defibrinated serum was treated with NaCl (final mass concentration 50 g/L, Sigma-
Aldrich, DE) and the pH adjusted to 8.5 with a saturated TRIS solution (Sigma-Aldrich, DE). 
The lipids present in the serum were removed by incubation for one hour at 4 °C with slow 
stirring (3087 g) with synthetic amorphous silica (430 mg/g of protein). Protein precipitates 
and silica particles were removed by centrifugation at 16880 g for 30 min. The clear 
supernatant was dialysed nine times against an isotonic NaCl solution  
(0.9 % w/v) (Sigma-Aldrich, DE) over 24 h. The pH was then adjusted to 7.2 with a  
100 mmol/L HEPES solution (Sigma-Aldrich, DE) and the following preservatives were 
added: sodium azide (final concentration of 0.95 g/L), aprotinin (final concentration of 61.5 
TIU/mL) and benzamidine hydrochloride monohydrate (final concentration of 1 mmol/L). All 
three preservatives were purchased from Sigma-Aldrich (DE). The serum was then filter- 
sterilised through a 0.22 µm PES filter (Corning Inc., US). 
3.2.3. Filling 
 
The serum was processed as a single batch at JRC. Firstly, 1 mL of serum was transferred 
to 2.5 mL siliconised hydrolytic class III clear glass vials using a Rota ampouling machine 
R910 PA (Rota, Wehr, DE). This process was completed in four hours. The ampouling 
machine and the continually stirred ice-cooled serum were placed in a movable class 1000 
clean room (Terra Universal Inc., Fullerton, California, US). The speed of the ampouling 
machine was optimised to minimise the formation of foam and achieve the accurate transfer 
of serum to the vials. Immediately after filling, lyophilisation inserts were manually placed in 
the neck of the vials. All vials were then loaded into a freeze dryer Epsilon2-100D (Martin 
Christ, Osterode, DE) for freeze-drying. After completion of the freeze-drying programme, the 
vials were filled with argon and the inserts were fully pressed down. Vials were manually 
capped, labelled and stored at -70 °C.  
4. Homogeneity 
A key requirement for any CRM aliquoted into units is the equivalence between those units. 
In this respect, it is relevant whether the variation between units is significant compared to 
the uncertainty of the certified value, but it is not relevant if this variation between units is 
significant compared to the analytical variation. Consequently, ISO Guide 34 requires 
reference material (RM) producers to quantify the between unit variation. This aspect is 
covered in between-unit homogeneity studies. For the evaluation of the homogeneity of the 
material, the values obtained from the one-year long-term stability study (at -70 ºC) were 
used. In the following chapters, data evaluation during a homogeneity study is described. 
4.1. Between-unit homogeneity 
 
The between-unit homogeneity was evaluated to ensure that the certified value of the CRM 
is valid for all vials of the material, within the stated uncertainty. 
For the between-unit homogeneity assessment, the number of units selected corresponds to 
the approximate cubic root of the total number of units produced and therefore 14 units were 
selected using a random stratified sampling scheme, covering the whole batch (the same 
samples used for long-term stability, Section 5.2). Three independent samples were taken 
from each of these units, and analysed by a chemiluminescent immunoassay (QuantaFlash 
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PR3) on the same day. The measurements were performed under repeatability conditions in 
one day in a randomised manner, thereby facilitating the separation of a potential analytical 
drift from a trend in the filling sequence.  
Regression analyses were performed to evaluate potential trends in the filling sequence 
(Figure A1) as well as trends in the analytical sequence (Figure A2). No trends were 
observed.  
The dataset was assessed for consistency using Grubbs outlier tests with a confidence level 
of 99 % on the individual results and the unit means. No outlying individual results or outlying 
unit means were detected.  
Quantification of between-unit inhomogeneity was undertaken by analysis of variance 
(ANOVA), which separates the between-unit variation (sbb) from the within-unit variation (swb). 
The latter is equivalent to the method repeatability if the individual samples are 
representative for the whole unit.  
Evaluation by ANOVA requires mean values per unit which follow at least a unimodal 
distribution and results for each unit that follow unimodal distributions with approximately the 
same standard deviations. The distribution of the mean values per unit was visually 
assessed using histograms and normal probability plots. Minor deviations from unimodality of 
the individual values do not significantly affect the estimate of between-unit standard 
deviations. The results of the statistical evaluation of the homogeneity studies at a 95 % 
confidence level show that the material is sufficiently homogeneous for its intended use. 
It should be noted that sbb,rel and swb,rel are estimates of the true standard deviations and are 
subject to random fluctuations. Therefore, the mean square between groups (MSbetween) can 
be smaller than the mean squares within groups (MSwithin), resulting in negative arguments 
under the square root used for the estimation of the between-unit variation, whereas the true 
variation cannot be lower than zero. In this case, u*bb, the maximum inhomogeneity that could 
be hidden by method repeatability, was calculated as described by Linsinger et al. [12]. u*bb is 
comparable to the limit of detection of an analytical method, yielding the maximum 
inhomogeneity that might be undetected by the given study setup.  Method repeatability 
(swb,rel), between–unit standard deviation (sbb,rel) and u*bb,rel were calculated as:  
y 
within
rel,wb
MS
s =  Equation 1 
y
n
MSMS
s
withinbetween
rel,bb
−
=  Equation 2 
y
νn
MS
u
MSwithin
within
*
rel,bb
4
2
=  Equation 3 
MSwithin mean square within a unit from an ANOVA  
MSbetween mean squares between-unit from an ANOVA 
y  mean of all results of the homogeneity study 
n mean number of replicates per unit 
MSwithinν  degrees of freedom of MSwithin  
 
13 
The results from the homogeneity studies are shown in Annex A, Table A1. For the 
calculation of the overall uncertainty, the sbb value was used. The results of the evaluation of 
the between-unit variation are summarised in Table 1. The values from the equations above 
were converted into relative uncertainties.  
 
Table 1: Results of the homogeneity study 
CRM 
swb,rel 
[%]
 
sbb,rel 
[%]
 
u*bb,rel 
[%] 
ERM-DA483/IFCC 1.87 0.96 0.56 
 
4.2. Within-unit homogeneity and minimum sample intake 
 
The minimum sample intake is the minimum amount of sample which is shown to be 
representative for the whole unit and can thus be used in an analysis. The within-unit 
homogeneity is correlated with the minimum sample intake and therefore sample sizes equal 
or above the minimum sample intake guarantee the certified value within its stated 
uncertainty.  
The smallest sample intake tested was identified after consideration of the method 
information supplied by the participants, the results of the homogeneity/stability experiments 
and from the characterisation study. In all cases ELISA based methods were used. The 
smallest sample intake used was 5 µL and was established as the minimum sample intake, 
as it resulted in consistent measurement results.  
The standard deviation within a bottle (swb) is lower than the expected method variability  
(i.e. < 5 % as set in our selection criteria), so there is no indication of intrinsic heterogeneity 
at a sample intake of 5 µL. 
 
5. Stability 
Stability testing is necessary to establish the conditions for storage (long-term stability) as 
well as the conditions for dispatch of the material to the customers (short-term stability). 
During transport, especially in summer time, ambient temperatures can reach 60 °C and 
therefore stability under these conditions must be demonstrated if the material is to be 
transported at ambient temperatures without additional cooling. 
The stability studies were performed using an isochronous design [13]. In this approach, 
units were stored for a specified length of time at different temperatures whereupon the units 
were moved to conditions where further degradation was assumed to be negligible 
(reference conditions). At the end of the isochronous storage, the samples were analysed 
simultaneously under repeatability conditions. Analysis of the material (after various 
exposure times and temperatures) under repeatability conditions greatly improves the 
sensitivity of the stability tests. The data were analysed by calculating the regression line for 
protein mass concentration in relation to time, and determining whether the slope is 
significantly different from zero. 
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5.1. Short-term stability study 
 
During the short-term stability study, units were stored at -20 °C, 4 °C and 18 °C for 0, 1, 2 
and 4 weeks whereupon  they were moved to the reference temperature of at most -150 °C, 
where further degradation is avoided. Two units per storage time were selected using a 
random stratified sampling scheme. Three samples, taken from each unit, were analysed by 
ORG 618 anti-PR3 hs ELISA under repeatability conditions in a randomised sequence, to be 
able to separate a potential analytical drift from a trend over storage time. The values were 
corrected for the variable reconstitution volume.  
The data were evaluated for each temperature individually. The results were screened for 
outliers using the single and double Grubbs test. For every temperature there were  
24 measurements performed.  
Furthermore, the data were evaluated against storage time and regression lines of protein 
mass concentration versus time were calculated. The slope of the regression line was tested 
for statistical significance (loss/increase due to shipping conditions) and was found not to be 
significantly different from zero. However, the usts calculated from the data was rather large.  
Therefore the data from the long-term stability study performed at -70 °C (Section 5.2) were 
used for the assessment of the uncertainty relating to transport (usts). During shipment at 
temperatures of -70 °C or below, the uncertainty associated with the short-term stability for a 
period of one month was 0.1 %, which is negligible with respect to other uncertainties. 
Therefore the material can be safely shipped at -70 °C or below.  
5.2. Long-term stability study 
 
During the long-term stability study, samples were stored at -20 °C and -70 °C for 0, 4, 8 and 
12 months, whereupon  they were moved to the reference temperature of at most -150 °C. 
Two units per storage time were selected using a random stratified sampling scheme. Three 
samples from each unit were analysed by a QuantaFlash PR3 chemiluminescent 
immunoassay under repeatability conditions, in a random sequence to be able to separate 
any potential analytical drift from a trend over storage time.  
The data were evaluated for each temperature individually. No outliers were found when the 
results were screened using the single and double Grubbs test. Furthermore, the data were 
plotted against storage time and linear regression lines of protein activity fraction versus time 
were calculated. The slope of the regression lines was assessed for statistical significance 
(loss/increase due to storage conditions). The slopes of the regression lines were not 
significantly different from zero (at a 95 % confidence level) for either temperature.  
No technically unexplained outliers were observed and none of the trends was statistically 
significant at a 95 % confidence level for any of the temperatures. Ideally the material should 
be stored for long periods of time at -70 °C. However, within the validity of the present 
certificate, the material can also be safely stored at -20 °C. 
The results of the long-term stability studies are shown in Annex B.  
 
5.3. Estimation of uncertainties 
 
Due to the intrinsic variation of measurement results, no study can entirely rule out 
degradation of materials, even in the absence of statistically significant trends. It is therefore 
necessary to quantify the potential degradation that could be hidden by the method 
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repeatability, i.e. to estimate the uncertainty of stability. This means, that even under ideal 
conditions, the outcome of a stability study can only report that there was no detectable 
degradation during the timeframe studied.  
Uncertainties of stability during dispatch and storage were estimated as described in [14]. In 
this approach, the uncertainty of the linear regression line with a slope of zero was 
calculated. The uncertainty contributions usts and ults are calculated as the product of the 
chosen transport time/shelf life and the uncertainty of the regression lines as: 
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RSD  relative standard deviation of all results of the stability study 
ti time elapse at time point i 
t  mean of all ti  
ttt chosen transport time (one week at -70 ºC) 
tsl chosen shelf life (12 months at -70 ºC) 
 
The following uncertainties were estimated: 
- usts,rel, the uncertainty of degradation during dispatch. This was estimated from the  
-70 °C studies. The uncertainty describes the possible change during a dispatch at  
-70 °C lasting for one week 
- ults,rel, the stability during storage. This uncertainty contribution was estimated from 
the -70 °C study. The uncertainty contribution describes the possible degradation 
during 12 months storage at -70 °C 
 
The results of these evaluations are summarised in Table 2. 
 
Table 2: Uncertainties of stability during dispatch and storage. usts,rel was calculated for 
dispatch for one week; ults,rel was calculated for storage for one year at -70 ºC 
CRM usts ,rel [%] 
ults,rel 
[%] 
ERM-DA483/IFCC 0.09 1.14 
 
Following the conclusion of the certification study, the material will be included in JRC's 
regular stability monitoring programme. 
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6. Characterisation  
The material characterisation is the process of determining the property value of a reference 
material. 
The characterisation of both the IgG PR3 ANCA solution serving as calibrant and of the 
candidate CRM was based on an inter-laboratory comparison of expert laboratories, i.e. the 
protein mass concentration of the material was determined in different laboratories that used 
their own methodology and instrumentation. This approach aims to negate the laboratory 
bias, thereby reducing the combined uncertainty.  
During the value assignment for the calibrant, the participant laboratories used turbidimetry 
and nephelometry for their measurements. For the characterisation of ERM-DA483/IFCC all 
participants used ELISA-type immunosorbent assays.  
 
6.1. Selection of participants 
Five laboratories were selected for the measurement of calibrant material and eight for the 
candidate CRM based on criteria that comprised of technical competence. Each participant 
was required to operate a quality system and to deliver documented evidence of proficiency 
in the field of in vitro diagnostics in relevant matrices by submitting results for 
intercomparison exercises or method validation reports. Holding a formal accreditation was 
not mandatory, but meeting the requirements of ISO/IEC 17025 [15] or ISO 15189 [16] was.  
 
6.2. General principles of the value assignment  
 
The laboratories were provided with detailed protocols in regard to the dilutions to be 
performed, reporting sheets, as well as with vials of the materials to be analysed. 
Laboratories were asked to specify the platform and reagents used, and the order in which 
the measurements were performed. The freeze-dried material of ERM-DA483/IFCC was 
reconstituted the day before the measurements, according to the procedure described in the 
certificate of ERM-DA470k/IFCC and in the present report (Section 9.3). 
 
Determination of the transfer factors 
During the transfer procedure calibration curves were constructed from the corresponding 
reference material or antibody preparation: ERM-DA470k/IFCC for the characterisation of the 
calibrant and purified IgG PR3 ANCA for the characterisation of ERM-DA483/IFCC. Based 
on these curves and the known concentration of the spiked material, the values of the target 
material were calculated. The relative mass concentrations were corrected for the masses of 
the dilutions (and predilution).  
During the value transfer procedure, the laboratories measured the eight dilutions of the 
target (Y0-Y7) and the calibrant (X0-X7) in triplicate, on each day. For both materials, single 
measurement results sijk (signal of the kth measurement of material i within dilution j, in g/L) 
were plotted in scatter plots sijk = f(cij) to facilitate the identification of outliers. A linear 
regression with intercept was performed on the means of the sijk in function of the 
concentration cij. 
The following analyses were performed on all data: 
-   Evaluation of the studentised residuals for the identification of outliers  
-   Test for normality (visual inspection and normal probability plot) 
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-   Test for linearity (visual inspection and evaluation of R2)  
-   Verification that the intercept ± four times the s covers the origin 
The transfer factors (TFs) were calculated as the ratio of the slopes of the linear regression 
lines for the candidate reference material and for the calibrant.  
The following general acceptance criteria were applied to the datasets: 
 
1. R2 of the regression must be above 0.98  
2. Data from at least four dilutions must be available 
3. The dataset from any one day must contain at least 50 % of the data generated. 
on that day, otherwise all of the data generated on that day are declared null and 
void 
4. At least two daily value assignments must be valid 
5. The day-to-day variation (RSD) of valid datasets for the protein and laboratory 
must be below 15 % 
 
6.3. Production of the calibrant 
6.3.1. Purification and physico-chemical characterisation 
of the calibrant 
 
The IgG PR3 ANCA was purified from human serum (provided by Statens Serum Institut, 
DK) in a three-step purification process. Firstly, total IgG was separated by affinity 
chromatography using a Protein A column. Secondly, the specific IgG PR3 ANCA was 
separated from all other IgGs eluting from the protein A column using an in-house tailored 
HiTrap column prepared using commercially available purified human proteinase 3 (Sigma-
Aldrich, US) and a HiTrap NHS activated HP column (GE Healthcare, SE) according to the 
protocol provided by the manufacturer. All IgG PR3 ANCA containing fractions were pooled, 
concentrated to a final volume of 500 µL using Amicon Ultra centricons with a 30 kDa cut-off 
(Millipore, US) and subsequently separated on a Superdex 200 10/300 GL column (GE 
Healthcare, SE). The purity of the final material with respect to IgG selectivity for PR3 was 
assessed by affinity chromatography using an in-house prepared IgG PR3 ANCA HiTrap 
column as described above. In the chromatograph a single fraction of protein was eluted 
under the acidic conditions of the eluting buffer (pH 2.7). A small fraction of the protein eluted 
in the binding buffer (pH 7.0). The area of this peak corresponding to IgG not specific for PR3 
ANCA was taken into consideration for the calculation of concentration of IgG PR3 ANCA in 
the calibrant and its uncertainty. The uncertainty value finally used with regard to the purity of 
the purified protein was equal to 1.6 %, corresponding to 50 % of the value for the impurity 
(IgG not selective for PR3 ANCA, chromatogram and peak areas not shown) (Table 3, 
Section 6.3.2). 
 
6.3.2. Value assignment of the calibrant 
 
During the characterisation of the calibrant (IgG PR3 ANCA), each laboratory received six 
vials containing various dilutions of purified IgG PR3 ANCA prepared at the JRC as well as 
six vials with dilutions of ERM-DA470k/IFCC for each day. Identical measurements were to 
be repeated over two days. The laboratories were therefore required to provide 36 
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independent results per material (three per dilution per day). Participating laboratories were 
instructed to use their in-house calibrant to determine the dose-response function of the 
instrument. The units for material characterisation were selected using a random stratified 
sampling scheme and covered the whole batch. Measurements were performed with 
different platforms (Annex C, Table C1) and reagents. In total five laboratories participated in 
the characterisation study. 
The concentration of the calibrant was measured by nephelometry or turbidimetry (Annex C, 
Table C1). The participating laboratories provided the mass concentration measured using 
their in-house calibrant for both, ERM-DA470k/IFCC and the purified IgG PR3 ANCA 
solution. Regression lines were constructed comparing these measured mass concentrations 
to the gravimetrically calculated dilution factors of these samples. The slope ratio of the 
ERM-DA470k/IFCC to the purified IgG PR3 ANCA was used to determine the value of the 
dilutions. 
 
The data were assessed for both their compliance with the analysis protocol and for their 
validity based on technical issues. The following criteria were considered during the 
evaluation:  
- Compliance with the analysis protocol: sample preparations and measurements 
performed on a minimum of two days, and the analytical sequence 
- Method performance, i.e. agreement of the measurement results with the assigned 
value of their in-house QC sample 
- R2 of the regression lines must be above 0.98 
 
Based on the criteria above, one dataset was rejected as not technically valid. The results 
provided from this laboratory did not comply with the criteria for the correlation coefficients, 
showing R2 values < 0.98. Another dataset was also rejected as the samples were analysed 
after long storage at -20 ºC, a temperature at which the protein is known to be unstable. 
The results of the individual accepted laboratories are given in Table C1 of the Annex C. 
The uncertainty relating to the characterisation of the calibrant (purified IgG PR3 ANCA) was 
estimated from the standard error of the mean of laboratory means (Table 3); the uncertainty 
of the reference material value used for the calibration (ERM-DA470k/IFCC) as well the 
uncertainty of the purity of the material. The uncertainty resulting from the gravimetric 
preparation of the dilutions was found to be insignificant and was not taken into account for 
the final uncertainty of the calibrant (ubal,rel = 0.008 %). The value given for the mean mass 
concentration of the purified IgG PR3 ANCA is the corrected value after taking the purity 
assessment into account. 
Table 3: Uncertainty budget for purified IgG PR3 ANCA mass concentration 
Analyte p 
Mean Mass 
Concentration 
[mg/L] 
s [mg/L] uERM-DA470k,rel [%] 
uchar, cal rel 
[%] 
upur,rel 
[%] 
uIgG PR3 
ANCA,rel 
[%] 
IgG PR3 
ANCA 3 288.96 5.99 0.98 1.99 1.6 2.75 
 
These different contributions were combined to estimate the relative uncertainty of the mass 
concentration value of the calibrant (uIgG PR3 ANCA, rel) as:  
2
rel pur,
2
 C DA470k/IFC-ERM
2
rel cal, char uuuu ++= ANCA PR3IgG  Equation 6 
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- uchar,cal was estimated from the data in Annex C, Table C1  
- uERM-DA470k/IFCC was estimated during its certification [3] 
- upur was estimated as described in Section 6.3.1 
 
The concentration of the material was additionally determined by UV spectrophotometry at 
280 nm using an absorption coefficient of 1.36 (g/L)-1cm-1 (210000 M-1cm-1) [17]. The 
concentration which was measured on four separate days, in triplicate, was equal to  
301.17 mg/L. This value was not used for the value assignment of the candidate reference 
material nor in the calculation of the uncertainties, as the absorption coefficient -used for the 
calculations is based on an absorption coefficient determined in 1955 [17], and its 
determination is not sufficiently documented regarding its traceability.  
6.4. Characterisation of ERM-DA483/IFCC  
 
During the characterisation of the target material each laboratory received four vials of ERM-
DA483/IFCC and four vials of IgG PR3 ANCA. The laboratories were required to perform 
eight dilutions from each of these vials and to provide a total of 96 independent results, three 
per dilution, for each material. The vials for the material characterisation were selected using 
a random stratified sampling scheme and covered the whole batch. The sample preparations 
and measurements were to be spread over four days to ensure intermediate precision 
conditions. The dilution protocol was the same for both materials (5, 10, 20, 30, 40, 50, 75 
and 100 (m/m) % of the reconstituted materials). 
The techniques used to measure the protein concentration were traditional ELISA and in 
some cases its variations (chemiluminescent and fluorescence immunoassays) specific for 
IgG PR3 ANCA. In total eight laboratories participated in the value assignment, using ten 
different types of kits (Annex C, Table C2). 
 
The data were first assessed for compliance with the mandatory analysis protocol and for 
their validity based on technical issues. The following criteria were considered during the 
evaluation:  
- Compliance with the analysis protocol (sample preparations and measurements 
performed on a minimum of two days) and the analytical sequence 
- Method performance, i.e. agreement of the measurement results with the assigned 
value of their in-house QC sample 
- R2 of the regressions either linear or logarithmic above 0.98 for data on all platforms  
 
Linear regressions were used for the analyses of the data provided by the methods 1-4 and 
6-8 (Annex C, Table C2). However, for methods 5, 9 and 10 the data provided were following 
a non-linear distribution and were therefore treated accordingly.  
Based on the criteria above, data derived from the second day for method 1, and the first day 
for method 5, were not taken into consideration as their R2 values were below the set limit of 
0.98. Additionally for laboratory 6, two out of the four days had correlation coefficients below 
0.98 and thus the data from those two days were not taken into account for the final value 
assignment.  
The accepted datasets were tested for normality of dataset means using normal probability 
plots and were tested for outlying means using the Grubbs test and for outlying standard 
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deviations using the Cochran test (both at a 99 % confidence level). Standard deviations 
within (swithin) and between (sbetween) laboratories were calculated using one-way ANOVA. 
The laboratory means follow normal distributions. None of the data contained outlying means 
and variances. The datasets were therefore consistent and the mean of laboratory means 
was a good estimate of the true value. Standard deviations between laboratories are 
considerably larger than the standard deviation within laboratories, showing that confidence 
intervals of replicate measurements are unsuitable as estimate of measurement uncertainty. 
It was verified however, that there was an overlap between the mean of all means plus/minus 
the standard deviation and the mean for individual laboratories, plus/minus the standard 
deviation for the individual laboratories (Figure C1). 
The value assignment data of the individual laboratories are shown in Annex C, Table C3. 
6.4.1. Mass concentration and characterisation 
uncertainty  
 
The mass concentration of IgG PR3 ANCA in ERM-DA483/IFCC was calculated from the 
average of the TF (Annex C, Table C3) and the protein concentration obtained for the 
calibrant (Table 3, 3rd column) according to: 
cERM-DA483/IFCC = TFaverage · cIgG PR3 ANCA 
Where cIgG PR3 ANCA is the concentration of IgG PR3 ANCA (calibrant) and TFaverage is the 
mean of means for all four analyses days and for all participating laboratories as described in 
Section 6.4. 
The uncertainty relating to the characterisation of the mass concentration for IgG PR3 ANCA 
in ERM-DA483/IFCC was estimated as the standard error of the mean of laboratory means 
(Table 4). 
 
Table 4: Value assignment for mass concentration for IgG PR3 ANCA in ERM-
DA483/IFCC 
CRM p Mean [mg/L] s [mg/L] uchar, rel  [%] 
ERM-DA483/IFCC 10 270.27 36.88 4.32 
 
7.  Value assignment 
Certified values are values that fulfil the highest standards of accuracy. Internal quality 
management procedures require no less than six technically valid datasets to assign certified 
values. Full uncertainty budgets in accordance with the 'Guide to the Expression of 
Uncertainty in Measurement' [7] were established. A certified value for the mass 
concentration of IgG PR3 ANCA was assigned to ERM-DA483/IFCC. 
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7.1. Certified values and their uncertainties  
 
The mass concentration of IgG PR3 ANCA in ERM-DA483/IFCC was calculated as 
described in section 6.4.1. It was derived from the unweighted mean of the means of the TFs 
of the individual laboratories (Annex C, Table C3) and the IgG concentration for the calibrant 
(Table 3, 3rd column). 
The assigned uncertainty consists of uncertainties relating to the characterisation of the 
target material, uchar (Section 7), to the combined uncertainty of the characterisation of the 
calibrant uchar,cal (Section 6), to the potential between-unit inhomogeneity, ubb (Section 4) and 
to the potential degradation during transport (usts) and long-term storage, ults (Section 5) as 
selected at -70 ºC. The uncertainty relating to the use of analytical balance during the 
gravimetric preparation of the dilutions of the calibrant was found to be negligible (equal to 
0.008 %) [3]. The different contributions were combined to estimate the expanded, relative 
uncertainty of the certified value (UCRM, rel) with a coverage factor k as:  
 
2
rel lts,
2
rel sts,
2
rel bb,
2
rel cal, char,
2
rel char,rel CRM, uuuuukU ++++⋅=  Equation 7 
 
- uchar was estimated as described in Section 7.1  
- uchar,cal was estimated as described in Section 6.3.2 
- ubb was estimated as described in Section 4.1 
- usts was estimated as described in section 5.3 
- ults was estimated as described in Section 5.3 
 
The relative expanded uncertainty was calculated from the relative combined standard 
uncertainty uCRM,rel by multiplication with a coverage factor k (UCRM = uCRM * k). A coverage 
factor of two was taken as there are sufficient degrees of freedom for the different uncertainty 
contributions. The relative expanded uncertainty was multiplied by the mean of dataset 
means to obtain the expanded uncertainty UCRM. 
The uncertainty budget after taking into consideration the various uncertainty contributions 
and the relative combined uncertainty (uCRM,rel) is shown in Table 5. 
Table 5: Uncertainty budget for the IgG PR3 ANCA mass concentration in ERM-
DA483/IFCC 
CRM  uIgG PR3 ANCA rel  [%] uchar, rel [%] 
ubb, rel 
[%] 
usts, rel 
[%] 
ults, rel 
[%] 
uCRM,rel 
[%] 
UCRM 
[mg/L] 
ERM-DA483/IFCC 2.75 4.32 0.97 0.09 1.14 5.33 29 
 
Finally, the certified value for the IgG PR3 ANCA mass concentration in ERM-DA483/IFCC 
and its accompanying uncertainty are shown in Table 6.  
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Table 6: Mass concentration of IgG PR3 ANCA in ERM-DA483/IFCC 
 Certified value  
[mg/L] 
Uncertainty  
[mg/L] 
IgG PR3 ANCA  270 29 
8. Metrological traceability and commutability 
8.1. Metrological traceability  
 
Identity 
The identity of IgG PR3 ANCA measured in ERM-DA483/IFCC is defined by the 
immunoassay procedures used to characterise it. The assigned property value is therefore 
operationally defined by method. 
 
Quantity value 
The certified value for the IgG PR3 ANCA mass concentration in ERM-DA483/IFCC was 
obtained by using different immunoassays specific for IgG PR3 ANCA and purified IgG PR3 
ANCA used as calibrant (Figure 2). The value for the total IgG concentration in this calibrant 
was previously obtained using immunoassays for total IgG mass concentration by calibrating 
with ERM-DA470k/IFCC. The mass concentration of total IgG present in ERM-DA470k/IFCC 
was certified using total IgG immunoassays using a certified reference material (ERM-
DA470/IFCC) as calibrant. Finally, the total IgG present in this last material and its 
uncertainty are traceable to the stated value of the mass concentration of total IgG in USNRP 
12-0575C [18]. The procedures applied are described in the certification report of ERM-
DA470k/IFCC [19] and in the present report (Figure 2). 
The certified value for the IgG PR3 ANCA mass concentration in ERM-DA483/IFCC is 
traceable to stated value of the mass concentration of total IgG in USNRP 12-0575C [18]. 
The value transfer measurements were strictly controlled with respect to adherence to the 
procedure and the adequate functioning of equipment and reagents was verified. Different 
combinations of reagents and platforms were used, which gave consistent results. Therefore 
the certified value for ERM-DA483/IFCC is not dependent on the individual methods used. 
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Figure 2: Reference materials and methods used for establishing the metrologically 
traceability chain (arrows facing upwards) and calibration sequence (arrows facing 
downwards) 
8.2. Commutability 
 
Many measurement procedures include one or more steps, which select specific analytes 
from the sample for the subsequent steps of the measurement process. It is difficult to mimic 
all the analytically relevant properties of real samples within a CRM. The degree of 
equivalence in the analytical behaviour of real samples and a CRM with respect to various 
measurement procedures (methods) is summarised in a concept called 'commutability of a 
reference material'. There are various definitions expressing this concept. For instance, the 
CSLI Guideline C-53A [11] recommends the use of the following definition for the term 
commutability: 
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"The equivalence of the mathematical relationships among the results of different 
measurement procedures for an RM and for representative samples of the type intended 
to be measured." 
The commutability of a CRM defines its fitness for use and, thus, is a crucial characteristic for 
the application of different measurement methods. When the commutability of a CRM is not 
established, the results from routinely used methods cannot be legitimately compared with 
the certified value to determine whether a bias in calibration exists or not, nor can the CRM 
be used as a calibrant. For instance, CRMs intended to be used for establishing or verifying 
metrological traceability of measurement results for routine clinical measurement procedures 
must be commutable for the routine clinical measurement procedures for which they are 
intended to be used. 
Different formats of materials, all based on the same raw material as ERM-DA483/IFCC, 
have been tested and found to be commutable for combinations of six methods giving 
correlating results (Annex D, Table D1). Therefore ERM-DA483/IFCC is expected to be 
commutable for the majority of IgG PR3 ANCA methods. However, if another method is used 
other than those included here then commutability should be verified. 
9. Instructions for use 
9.1. Safety information 
 
The laboratory safety measures apply. The plasmapheresis material used in the production 
of the material has been tested and found negative for Hepatitis B surface antigen, HIV 1&2 
antibodies, HIV antigen and Hepatitis C antibodies. However, the product must be handled 
with care as any material of human origin. It is intended for in vitro analysis only. 
9.2. Storage conditions 
 
Unopened vials should be stored at either -20 °C or -70 °C, as the material has been shown 
to be stable at both temperatures for up to one year. If microbial contamination has been 
excluded during the reconstitution procedure, the solution of ERM-DA483/IFCC can be used 
for one week. It is advisable to cover the vial with the original seal after use and to store it at  
2 to 8 °C.  
Please note that the European Commission cannot be held responsible for changes that 
occur during storage of the material at the customer's premises. 
9.3. Reconstitution and use of the material  
 
The material must be reconstituted according to the following procedure: 
• Remove the vial from the freezer and place it in the room where the balance is located 
one hour before reconstitution.  
• Prior to reconstitution, tap the bottom of the vial gently on the surface of the table. Make 
sure that all the material has settled down on the bottom of the vial. Remove the screw 
cap. 
• Weigh the vial together with the rubber stopper. Note the mass or press the “TARE” 
button on the balance. Lift carefully the rubber stopper until the groove. 
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• Add 1.00 mL of milli Q water through the groove, and press the rubber stopper back into 
place. Weigh the vial and note the mass. If you have used the “TARE” function, the value 
can be used directly for the mass m. Otherwise the first mass must be subtracted from 
the second to obtain m. 
• The concentration of a particular protein in the solution, corrected for the reconstitution 
mass, can be obtained by multiplying the certified value for that protein with mintended / m, 
with mintended the mass intended to be added (1.0000 g).  
• Leave the vial at RT for one hour, then gently mix by inversion at least five times (do not 
shake it) during the next hour. 
• Leave the vial at room temperature overnight. The following day, gently mix by inversion 
five times in a period of one hour, prior to starting the analysis. 
 
9.4. Minimum sample intake 
 
The entire contents of the vial must be reconstituted. The minimum sample intake after 
reconstitution is 5 µL. 
 
9.5. Use of the certified value 
 
The main purpose of this material is to be used for the calibration of immunoassay-based in 
vitro diagnostic devices or control products for IgG PR3 ANCA measurements. As any 
reference material, it can also be used for control charts or validation studies. 
When the material is used as a calibrant commutability should be verified for the assay 
concerned.  
 
Comparing an analytical result with the certified value 
A result is unbiased if the combined standard uncertainty of measurement and certified value 
covers the difference between the certified value and the measurement result (see also ERM 
Application Note 1, www.erm-crm.org [20].  
To assess the method performance, the measured values of the CRMs are compared with 
the certified values. The procedure is described here in brief:  
- Calculate the absolute difference between mean measured value and the certified 
value (∆meas) 
- Combine measurement uncertainty (umeas) with the uncertainty of the  
certified value (uCRM): 22 CRMmeas uuu +=∆  
- Calculate the expanded uncertainty (U∆) from the combined uncertainty (u∆,) using an 
appropriate coverage factor, corresponding to a level of confidence of approximately 
95 % 
- If ∆meas ≤ U∆ no significant difference between the measurement result and the 
certified value, at a confidence level of about 95 % exists 
Use in quality control charts 
The materials can be used for quality control charts. Different CRM-units will give the same 
result as inhomogeneity was included in the uncertainties of the certified values.  
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Annexes 
Annex A: Results of the homogeneity measurements 
 
  
 
Figure A1: Measured values (in Relative Light Units) as a function of the filling sequence. 
The error bars indicate the relative standard deviation between the triplicate measurements 
 
 
 
 
Figure A2: Measured values (in Relative Light Units)  as a function of the analytical 
sequence. In the graph values of all replicates are shown (● replicate 1, ▲ replicate 2 and ■ 
replicate 3) 
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Annex B: Results of the long-term stability measurements 
 
Figure B1: Long-term stability data (mean values) of ERM-DA483/IFCC; Measured values by 
a chemiluminescent immunoassay (Relative Light Units), when stored up to one year at  
-20 °C. Results at time point 0 months correspond to units that were stored at the reference 
temperature at most of -150 °C. 
 
 
 
Figure B2: Long-term stability data (mean values) of ERM-DA483/IFCC; Measured values by 
a chemiluminescent immunoassay (Relative Light Units), when stored up to one year at  
-70 °C. Results at time point 0 months correspond to units that were stored at the reference 
temperature at most of -150 °C. 
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Annex C: Characterisation 
 
IgG PR3 ANCA 
Laboratory  Platform Method Principle 
Mass 
Concentration 
[mg/L] 
L1 Cobas 6000/8000 c 501 Turbidimetry 294.85 
L2 Cobas c 501 Turbidimetry 295.26 
L3 Behring Nephelometer ( BN ) II Nephelometry 305.42 
 
Table C1: All laboratories giving acceptable results, together with the platforms used and the 
principles of the methods that these platforms employ are listed. The concentration given 
represents the average values of tree replicates over two days under intermediate precision 
conditions. 
 
 
ERM-DA483/IFCC 
Laboratory Method Number Method Name Method Principle 
Mass 
Concentration 
[mg/L] 
L1 1 
ImmuLisa™ Proteinase 
3 (PR3) antibody 
Enhanced 
ELISA 333.63 
L2 2 ORG 618 PR3 hs ELISA 319.75 
L3 
3 BioPlex 2200 Vasculitis Multiplex Flow Immunoassay 252.95 
4 Anti-PR3 EIA ELISA 247.58 
L4 
5 QUANTA Lite PR 3 ELISA 219.43 
6 QUANTA Flash Chemiluminescent immunoassay 255.01 
L5 7 PR3 ANCA Wieslab® ELISA 258.59 
L6 8 AESKULISA PR3 
sensitive ELISA 238.77 
L7 9 EliA PR3s Fluorescence immunoassay 275.33 
L8 10 Anti-PR3-hn-hr-ELISA (IgG) ELISA 301.77 
 
Table C2: All laboratories participating in the value assignment of the target material. The 
methods they used and the principles that these methods employ are listed. The last column 
gives the average concentrations of the ERM-DA483/IFCC.  
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ERM-DA483/IFCC 
Laboratory Method Number 
Slope 
ratio 
Day 1  
Slope 
ratio 
Day 2 
Slope 
ratio 
Day 3 
Slope 
ratio 
Day 4 
TF 
[mean 
slope 
ratio] 
Day-to-
Day 
variation 
[%]  
L1 1 1.254 n.i. 1.024 1.186 1.155 0.102 
L2 2 1.126 1.068 1.081 1.151 1.107 0.035 
L3 
3 0.782 0.891 0.988
 0.840 0.875 0.100 
4 0.695 0.891 0.992 0.849 0.857 0.144 
L4 
5 n.i. 0.782 0.780 0.717 0.759 0.049 
6 0.864 0.835 0.991 0.840 0.882 0.083 
L5 7 0.820 1.034 0.894 0.832 0.895 0.110 
L6 8 n.i. 0.897 0.755 n.i. 0.826 0.122 
L7 9 1.104 0.916 0.974 0.818 0.953 0.125 
L8 10 1.023 1.067 1.028 1.059 1.044 0.021 
n.i.: results not included due to technical reasons 
 
Table C3: Individual results for the value assignment for the characterisation of the target 
material, ERM-DA483/IFCC. The day-to-day variation per laboratory is presented.  
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L8-10
L7-9
L6-8
L5-7
L4-6
L4-5
L3-4
L3-3
L2-2
L1-1
St. Dev
[mg/L]
 
 
Figure C1: Mean values of the concentration (mg/L) of IgG PR3 ANCA for all participating 
laboratories and their corresponding standard deviations for the value transfer of  
ERM-DA483/IFCC 
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Annex D: Commutability 
Laboratory Method Name Method Principle 
L1 Varelisa™ PR3 ANCA ELISA 
L2 Wieslab® Anti-PR3 ELISA ELISA 
L3 anti-PR3-hr-hn ELISA (IgG) ELISA 
L4 QUANTA Lite PR3 IgG ELISA 
L5 ORG 518 Anti-PR3 (cANCA) ELISA 
L6 DIASTAT anti-PR3 (cANCA) ELISA 
Table D1: Laboratories that participated in the commutability studies and the methods for 
which pilot batches processed in the same way as ERM-DA483/IFCC were found to be 
commutable. 
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